Kyverna Therapeutics to Present at Upcoming Investor Conferences
Rhea-AI Summary
Kyverna Therapeutics (Nasdaq: KYTX) announced that management will present at two upcoming investor conferences: the H.C. Wainwright 4th Annual Nasdaq BioConnect Conference on May 19, 2026 at 2:30 p.m. ET and the Jefferies Global Healthcare Conference on June 3, 2026 at 3:10 p.m. ET. Live webcasts and 90-day replays will be available in the Investors section of Kyverna’s website.
Positive
- None.
Negative
- None.
News Market Reaction – KYTX
In the May 14 session, KYTX declined 0.37%, reflecting a mild negative market reaction. Argus tracked a trough of -9.0% from its starting point during tracking. Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that company management will present at the following upcoming conferences:
H.C. Wainwright 4th Annual Nasdaq BioConnect Conference
Format: Fireside chat and investor meetings
Date: Tuesday, May 19th, 2026
Time: 2:30 p.m. ET
Jefferies Global Healthcare Conference
Format: Corporate presentation and investor meetings
Date: Wednesday, June 3rd, 2026
Time: 3:10 p.m. ET
Live webcasts of the presentations may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. Replays of the webcasts will be available on the website for 90 days following the conference.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical biopharmaceutical company focused on liberating autoimmune patients through the curative potential of cell therapy. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome and an ongoing registrational trial for generalized myasthenia gravis. The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis and rheumatoid arthritis, to inform the next priority indications. Additionally, its next generation pipeline includes CAR T-cell therapies deploying novel innovations to improve patient access and experience. For more information, please visit https://kyvernatx.com.
Contact:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com
